ArticleScientific reports2026
Research on the effects of desflurane and sevoflurane on proliferation and migration of breast cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aimed to evaluate the biological effects of sevoflurane and desflurane on breast cancer cell lines representing different molecular subtypes under in vitro conditions. Specifically, the effects of these inhalational anesthetic agents on parameters associated with cancer progression, including cell proliferation, colony formation, apoptosis, and migration, were comparatively investigated. Triple-negative breast cancer cells (MDA-MB-231), estrogen receptor-positive cells (MCF-7), and non-tumorigenic breast epithelial cells (MCF-10 A) were used. Cells were exposed to clinically relevant concentrations of sevoflurane (3.6%) and desflurane (10.3%) for 3 h, followed by 24 h of incubation. Cell viability (MTS assay), colony formation, wound healing (migration), Annexin V apoptosis analysis, and Western blot analysis of apoptosis-related proteins were performed. Exposure to desflurane and sevoflurane significantly reduced the viability of MDA-MB-231 and MCF-7 cells (p < 0.0001), whereas no significant change was observed in MCF-10 A cells. Colony formation was significantly suppressed only in MDA-MB-231 cells, with a more pronounced effect observed following desflurane exposure. Neither agent significantly affected cell migration. Apoptosis rates significantly increased in MDA-MB-231 cells treated with desflurane (p < 0.0001). Western blot analysis demonstrated that desflurane increased p53 expression in MDA-MB-231 cells, whereas sevoflurane reduced its expression; no significant alterations were observed in PARP-1 and AIF levels. These findings suggest that desflurane exerts proliferation-inhibitory and apoptosis-inducing effects, particularly in triple-negative breast cancer cells. Sevoflurane demonstrated comparatively weaker effects. Overall, our results indicate that volatile anesthetics may directly influence cancer cell biology; however, their clinical implications require further validation in in vivo and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.